BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 18272249)

  • 1. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
    Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
    Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
    Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
    Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
    Lee JE; Park HS; Jung SS; Kim JO; Kim SY
    Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
    Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
    Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
    J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
    Sohn JH; Moon YW; Lee CG; Kim GE; Chung KY; Chang J; Kim SK; Kim YS; Choi BW; Choi HJ; Kim JH
    Cancer; 2007 May; 109(9):1845-950. PubMed ID: 17366589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
    Han JY; Lee DH; Lee SY; Park CG; Kim HY; Kim EA; Yoon SM; Lee HG; Lee JS
    Med Oncol; 2005; 22(3):281-90. PubMed ID: 16110139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
    Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
    Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
    Kudoh S; Fujiwara Y; Takada Y; Yamamoto H; Kinoshita A; Ariyoshi Y; Furuse K; Fukuoka M
    J Clin Oncol; 1998 Mar; 16(3):1068-74. PubMed ID: 9508192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
    Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
    Jeong HC; Lee SY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    Lung Cancer; 2006 Sep; 53(3):361-6. PubMed ID: 16846662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
    Briasoulis E; Samantas E; Kalofonos H; Skarlos D; Makatsoris T; Christodoulou C; Fountzilas G; Bamias A; Dimopoulos MA; Kosmidis P; Pavlidis N
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):521-8. PubMed ID: 15959778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.
    Takigawa N; Fujiwara K; Ueoka H; Kiura K; Tabata M; Hiraki A; Shibayama T; Segawa Y; Kamei H; Hiraki S; Tanimoto M; Harada M
    Anticancer Res; 2003; 23(1B):557-60. PubMed ID: 12680145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.